clinical trial · NCT07415044
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company·phase2·recruiting·n = 1,431
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active SevereLY4268989Placebo
brief summary
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding screening.
started
Mar 26, 2026
primary completion
Jun 1, 2030
completion
Jul 1, 2031
last updated
Jun 4, 2026
official title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol